N/A N=1,826 Agrylin Drug Use-Result Survey
Essential Thrombocythemia (ET)
Primary: Number of Participants Who Had One or More Adverse Events — 776 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=193 Phase II Study of BNC210 in PTSD
Post-Traumatic Stress Disorder
Primary: Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score — 15.26…
Phase 2 N=701 FEnofibRate as a Metabolic INtervention for COVID-19
Covid19
Primary: Primary Hierarchical Composite Endpoint — 5.32; 5.33 Ranked Severity Score
N/A N=85 Clinic to Community Connections - Broader Distribution
Gestational Diabetes · Gestational Diabetes Mellitus in Pregnancy
Primary: Staff - Self-efficacy to Provide Diabetes Education Questionnaire (Newly Developed) — 6.60; 9.33 units on a scale — p=<0.0001
N/A N=25 Low-Level Laser Therapy for Prevention of Oral Mucositis
Mucositis
Primary: Number of Participants With Severe (Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v. 4.0] Grade 3-5 Oral Mucositis in Patients Treated to a…
Phase 4 N=55 Acthar Gel in Participants With Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: DBT: Number of Participants in Each Category of Assessment Based on Forced Vital Capacity (FVC), a Pulmonary Function Test Parameter at Week 24 — 10; 7; 12; 12…
N/A N=6 Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer
Pancreatic Cancer
Primary: Safety Endpoint — 6; 0 Participants
Phase 2 N=295 Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Myocardial Infarction
Primary: Left Ventricular Ejection Fraction Assessed by Cardiac Magnetic Resonance Imaging (CMRI) — 5.6; 5.3; 5.7 percentage of left ventricular volumes
Phase 2 N=71 Translational Neuroscience Optimization of GlyT1 Inhibitor
Cognitive Impairments Associated With Schizophrenia
Primary: Change in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 28.15; 25.22; 31.71; 28.3 score on scale
N/A N=51 tDCS for Increasing Exercise Adherence in Depressed Individuals
Depression · Physical Activity
Primary: Physical Activity Levels — 17.4; 21.0 minutes per day — p=.87
Phase 3 N=245 Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 15.96; 17.71 mmHg — p=<0.00001
Phase 2 N=72 Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
N/A N=1,492 The Etiology of Acute Febrile Illness Requiring Hospitalization
Acute Febrile Illness
Primary: The Etiologies (Bacteria, Viruses, Parasites, Fungi and Others) of Fever Illness Expressed in Percentages of Enrolled Subjects. — 621; 362; 15; 5 Participants
N/A N=50 Wayfinding Intervention in High-Fidelity Long-Term Memory
Long-Term Memory Decline · Mild Cognitive Impairment
Primary: MDT Change in Mnemonic Discrimination — 0.09; 0.01 LDI score on a scale — p== 0.016
N/A N=21 ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection
Aortic Dissection
Primary: All Cause Mortality at 30 Days Post-procedure — 3 Participants